The development of thyroid antibodies and the alteration of thyroid function are the most common disorders associated with interferon alfa therapy in individuals with chronic hepatitis C (CHC).
In this study, we compared the course of Graves disease (GD) between patients diagnosed with CHC and treated with interferon alfa and uninfected patients.
Methods
We retrospectively analyzed data from 39 GD patients (15 men and 24 women, group 1) affected by CHC and treated with interferon alfa and from 43 uninfected GD patients (19 men and 24 women, group 2) who were seen at our institution from 1999 to 2011. All GD patients were treated with methimazole (MMI). Daily dose of MMI, duration of MMI therapy, and remission rate were evaluated in both groups.
Results
The daily dose of MMI was found to be lower in group 1 as compared with group 2 (9.74 ± 5.94 mg/d vs 14.12 ± 8.64 mg/d in group 1 vs group 2, respectively, P < 0.01). In addition, the duration of MMI treatment was found to be lower in group 1 as compared with group 2 (13.98 ± 13.0 months vs 38.86 ± 27.13 months in group 1 vs group 2, respectively; P < 0.01). The remission rate from GD was higher in the patients of group 1 in comparison with the patients of group 2 (87.17 % vs 48.86% in group 1 vs group 2, respectively, P < 0.005).
Conclusion
Altogether, our data demonstrate a more favorable course of GD in the patients with CHC treated with interferon alfa compared with GD occurring in the patients without CHC.
TomerY, BlackardJT, AkenoN. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007; 36 (4): 1051–1066.
2.
NadeemA, HussainMM, AslamM, . Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C. Hepat Mon. 2010; 10 (2): 132–140.
3.
WongV, FuAX, GeorgeJ, . Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf). 2002; 56 (6): 793–798.
4.
FentimanIS, ThomasBS, BalkwillFR, . Primary hipothyroidism associated with interferon therapy of breast cancer. Lancet. 1985; 1 (8438): 1166.
5.
BurmanP, TotermanTH, ObergK, . Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab. 1986; 63 (5): 1086–1090.
6.
TomerY, MenconiF. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab. 2009; 23 (6): 703–712.
7.
FoldesI, DavidK, HorvathG, . Thyroid dysfunctions in patients with viral hepatitis treated with interferon-alpha. Orv Hetil. 2004; 145 (23): 1211–1216.
8.
MoriscoF, MazziottiG, RotondiM. Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig Liver Dis. 2001; 33 (3): 247–253.
9.
BiniEJ, MehandruS. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med. 2004; 164 (21): 2371–2376.
10.
VasiliadisT, AnagnostisP, NalmpantidisG, . Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C. Ann Acad Med Singapore. 2011; 40 (9): 394–400.
KohLK, GreenspanFS, YeoPP. Interferon-induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid. 1997; 7 (6): 891–896.
Fernandez-SotoL, GonzalesA, Escobar-JimenezF. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998; 158 (13): 1445–1448.
15.
HsiehMC, YuML, ChuangWL, . Virologic factors related to interferon-alpha-induced thyroid disfunction in patients with chronic hepatitis C. Eur J Endocrinol. 2000; 142 (5): 431–437.
Lisker-MelmanM, DiBisceglie AM, UsalaSJ, . Development of thyroid disease during therapy of chronic viral hapatitis with interferon alfa. Gastroenterology. 1992; 102 (6): 2155–2160.
18.
TranA, QuarantaJF, BenzakenS. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993; 18 (2): 253–257.
19.
RotiE, MinelliR, GiubertiT, . Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996; 101 (5): 482–487.
20.
MazziottiG, SorvilloF, StornaiuoloG, . Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV related chronic hepatitis: a prospective studies. J Endocrinol Invest. 2002; 25 (7): 624–630.
21.
DalgardO, BjøroK, HellumK, . Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002; 251 (5): 400–406.
22.
HollowellJG, StaehlingNW, FlandersWD, . Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87 (2): 489–499.
23.
VanderpumpMPJ, TunbridgeWMG, FrenchJM, . The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf). 1995; 43 (1): 55–68.
24.
BahnRS, BurchHB, CooperDS, . Hyperthyroidism and other causes of thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21 (6): 593–646.
25.
MinelliR, RotiE. Interferone e tireopatie. Endocrinologo. 2000; 1 (2): 63–68.
26.
VillanuevaRB, BrauN. Graves’ ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid. 2002; 12 (8): 737–738.
27.
CarellaC, MazziottiG, MoriscoF, . Long-term outcome of interferon-alfa induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab. 2001; 86 (5): 1925–1929.
28.
DaviesFT. Graves’ disease: pathogenesis. In: UtigerRD, BravemanLEeds. The Thyroid. Philadelphia, PA: Lippincott Williams & Wilkins; 2000, pp 518–531.
29.
MinelliR, CoiroV, ValliMA, . Graves’ disease in interferon-α-treated and untreated patients with chronic hepatitis C virus infection. J Investig Med. 2005; 53 (1): 26–30.
30.
CorssmitEP, De MetzJ, SauerweinHP, . Biologic responses to IFN-α administration in humans. J Interferon Cytokine Res. 2000; 20 (12): 1039–1047.
31.
PfefferLM, DinarelloCA, HerbermanRB, . Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998; 58 (12): 2489–2499.
MandacJC, ChaundryS, ShermanKE, . The clinical and physiological spectrum of interferon-alpha induced thyroiditis: towards a new classification. Hepatology. 2006; 43 (4): 661–672.
34.
PreziatiD, La RosaL, CoviniG, . Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995; 132 (5): 587–593.
35.
CustroN, MontaltoG, ScafidiV, . Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest. 1997; 20 (7): 374–380.
